COGT vs. IMNM, AYTU, PBH, MRUS, HCM, ARWR, BHVN, FOLD, IDYA, and XENE
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Immunome (IMNM), Aytu BioPharma (AYTU), Prestige Consumer Healthcare (PBH), Merus (MRUS), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
Cogent Biosciences received 249 more outperform votes than Immunome when rated by MarketBeat users. Likewise, 70.62% of users gave Cogent Biosciences an outperform vote while only 69.44% of users gave Immunome an outperform vote.
Immunome has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Cogent Biosciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
In the previous week, Immunome had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Immunome and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.73 beat Immunome's score of 0.82 indicating that Cogent Biosciences is being referred to more favorably in the media.
44.6% of Immunome shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by company insiders. Comparatively, 8.6% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cogent Biosciences has a net margin of 0.00% compared to Immunome's net margin of -1,829.44%. Immunome's return on equity of -37.33% beat Cogent Biosciences' return on equity.
Cogent Biosciences presently has a consensus target price of $14.67, suggesting a potential upside of 74.81%. Immunome has a consensus target price of $29.80, suggesting a potential upside of 96.05%. Given Immunome's stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Cogent Biosciences.
Summary
Immunome beats Cogent Biosciences on 12 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
